• Vaxart faces a proxy fight at its July 16, 2026 annual meeting after shareholder Daniel P. Houle nominated a rival slate for three board seats.
• The board opposes Houle’s nominees, urging votes for its six director candidates on the company’s white universal proxy card.
• The company warned that electing all three Houle nominees would trigger a “change in control” under multiple equity and severance plans.
• Houle’s group reported ownership of 1,739,782 shares, about 0.7% of outstanding stock, including Houle’s 15,622 shares as of Feb. 20, 2026.
• Vaxart budgeted about $1.6 million in incremental contest costs, with about $700,000 incurred, including a $112,500 proxy solicitor fee.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxart Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-063160), on June 01, 2026, and is solely responsible for the information contained therein.